Sunday, May 16, 2021

COVID-19 drug Baricitinib: Eli Lilly signs voluntary licensing agreement with Natco Pharma

COVID-19 drug Baricitinib: Eli Lilly signs voluntary licensing agreement with Natco Pharma Natco has received approval from the Drug Controller General of India (DCGI) for Baricitinib earlier in May. Natco went ahead and launched the drug under brand name Barinat even as its compulsory licensing application is still pending before India. The patents of Baricitinib are owned by Lilly.

from Moneycontrol Business News https://ift.tt/3wc3SBq
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Sensex, Nifty slip 0.7% as Fed’s cautious outlook damps investor sentiment

Indian stock markets experienced a decline on Thursday. The NSE Nifty and BSE Sensex closed lower. This downturn followed the US Federal Res...